Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryMarch 28, 2017	Vericel to Present at the 16th Annual Needham Healthcare Conference CAMBRIDGE, Mass., March 28, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the 16 th	View HTML Vericel to Present at the 16th Annual Needham Healthcare Conference 10.4 KB
Toggle SummaryApril 10, 2017	Vericel Announces Appointment of Michael Halpin as Senior Vice President, Quality and Regulatory Affairs Accomplished Industry Veteran Brings Extensive Quality and Regulatory Affairs Experience in Cell and Gene Therapies and Medical Devices	View HTML Vericel Announces Appointment of Michael Halpin as Senior Vice President, Quality and Regulatory Affairs 13.3 KB
Toggle SummaryApril 20, 2017	Vericel to Present at the 5th Annual Cell & Gene Therapy Investor Day CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the 5th	View HTML Vericel to Present at the 5th Annual Cell & Gene Therapy Investor Day 10.3 KB
Toggle SummaryMay 4, 2017	Vericel to Host First-Quarter 2017 Earnings Webcast and Conference Call on May 10, 2017 CAMBRIDGE, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced the following webcast and conference call: What: Vericel	View HTML Vericel to Host First-Quarter 2017 Earnings Webcast and Conference Call on May 10, 2017 12.2 KB
Toggle SummaryMay 10, 2017	Vericel Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Ixmyelocel-T for the Treatment of Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy Ixmyelocel-T is the First Therapy to Receive the RMAT Designation for the Treatment of a Serious Cardiovascular Disease	View HTML Vericel Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Ixmyelocel-T for the Treatment of Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy 22.4 KB
Toggle SummaryMay 10, 2017	Vericel Licenses Product Portfolio to Innovative Cellular Therapeutics for Distribution in China, South Korea, and other Countries in Southeast Asia CAMBRIDGE, Mass. and SHANGHAI, China, May 10, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that it has entered into a License Agreement with	View HTML Vericel Licenses Product Portfolio to Innovative Cellular Therapeutics for Distribution in China, South Korea, and other Countries in Southeast Asia 22.4 KB
Toggle SummaryMay 10, 2017	Vericel Reports First-Quarter 2017 Financial Results Conference Call Today at 8:00am Eastern Time	View HTML Vericel Reports First-Quarter 2017 Financial Results 33.3 KB
Toggle SummaryJuly 13, 2017	Vericel to Host Symposium on MACI Implant for Treating Articular Cartilage Defects in the Knee at AOSSM 2017 Annual Meeting CAMBRIDGE, Mass., July 13, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, announced today that the company is hosting a symposium on the MACI ® (autologous	View HTML Vericel to Host Symposium on MACI Implant for Treating Articular Cartilage Defects in the Knee at AOSSM 2017 Annual Meeting 26.3 KB
Toggle SummaryJuly 26, 2017	Vericel to Host Second-Quarter 2017 Earnings Webcast and Conference Call on August 9, 2017 CAMBRIDGE, Mass., July 26, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced the following webcast and conference call: What: Vericel	View HTML Vericel to Host Second-Quarter 2017 Earnings Webcast and Conference Call on August 9, 2017 14.3 KB
Toggle SummaryAugust 9, 2017	Vericel Reports Second-Quarter 2017 Financial Results Revenue of $17.0 Million Represents a 32% Increase Over Second Quarter 2016 Results Driven by Momentum of MACI Uptake Following Launch Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of	View HTML Vericel Reports Second-Quarter 2017 Financial Results 33.6 KB

Investor Relations

Press Releases

Company Presentation